Please use this identifier to cite or link to this item: https://doi.org/10.1007/s13346-015-0240-4
Title: A biodegradable ocular implant for long-term suppression of intraocular pressure
Authors: Ng, X.W
Liu, K.L
Veluchamy, A.B 
Lwin, N.C
Wong, T.T 
Venkatraman, S.S
Keywords: elastomer
macrogol
poly(lactide co caprolactone)
timolol maleate
unclassified drug
antihypertensive agent
delayed release formulation
polymer
timolol
animal experiment
animal model
Article
biocompatibility
clinical examination
controlled study
disease course
drug delivery system
gel permeation chromatography
glaucoma
Haplorhini
in vitro study
in vivo study
intraocular pressure
lipophilicity
mathematical model
microfilm
nonhuman
ophthalmological implant
priority journal
sustained drug release
administration and dosage
animal
biodegradable implant
chemistry
delayed release formulation
drug effects
drug release
intraocular pressure
Macaca fascicularis
Ocular Hypertension
therapeutic use
Absorbable Implants
Animals
Antihypertensive Agents
Delayed-Action Preparations
Drug Delivery Systems
Drug Liberation
Intraocular Pressure
Macaca fascicularis
Ocular Hypertension
Polymers
Timolol
Issue Date: 2015
Citation: Ng, X.W, Liu, K.L, Veluchamy, A.B, Lwin, N.C, Wong, T.T, Venkatraman, S.S (2015). A biodegradable ocular implant for long-term suppression of intraocular pressure. Drug Delivery and Translational Research 5 (5) : 469-479. ScholarBank@NUS Repository. https://doi.org/10.1007/s13346-015-0240-4
Rights: Attribution 4.0 International
Abstract: Timolol maleate (TM) has been used for many years for the reduction of intraocular pressure (IOP) in glaucoma patients. However, the topical mode of administration (eyedrops) is far from optimal because of the issues of low bioavailability, high drug wastage, and lack of patient compliance. Suboptimal control of the IOP leads to disease progression and eventually to blindness. Ideally, TM is delivered to the patient so that its action is both localized and sustained for 3 months or more. In this work, we developed a subconjunctival TM microfilm for sustained, long-term delivery of TM to the eyes, using the biodegradable elastomer poly(lactide-co-caprolactone) (PLC). The copolymer is biocompatible and has flexibility and mechanical characteristics suitable for a patient-acceptable implant. Controlling the release of TM for 3 months is challenging, and this work describes how, by using a combination of multilayering and blending with poly(ethylene glycol) (PEG) copolymers, we were able to develop a TM-incorporated biodegradable film that can deliver TM at a therapeutic dose for 90 days in vitro. The data was further confirmed in a diseased primate model, with sustained IOP-lowering effects for 5 months with a single implant, with acceptable biocompatibility and partial degradation. © 2015, The Author(s).
Source Title: Drug Delivery and Translational Research
URI: https://scholarbank.nus.edu.sg/handle/10635/183743
ISSN: 2190393X
DOI: 10.1007/s13346-015-0240-4
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s13346-015-0240-4.pdf1.47 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

18
checked on Apr 19, 2021

Page view(s)

58
checked on Apr 15, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons